BehavioSec Expands Portfolio and Opens Market Access with Another Industry First
BehavioSec, industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced that it has extended its patented technology and BehavioSense platform into a SOC/ISO compliant, hosted-version and a cloud-native, SaaS version. These new versions will help more organizations meet compliance and cloud mandates, support frictionless multi-factor authentication (MFA), and gain access to the market’s most advanced behavioral biometrics technology – which until now – has only been employed within the world’s largest banks, e-Identity providers, and online retailers.
According to the recent July release of the 2021 Gartner ® Market Guide for Online Fraud Detection, “The convergence between online fraud detection (OFD), identity proofing and authentication continues with many organizations applying OFD capabilities to mitigate risk in identity proofing and authentication events.” The report further adds, “Banks are becoming increasingly comfortable with using vendor-hosted or SaaS solutions from vendors for transaction monitoring, which is a OFD capability that has traditionally been deployed on-premises in banking environments.” 1
As biometrics technology adoption increases and more companies look to hosted and SaaS-based solutions, the new SaaS-version of the company’s BehavioSense platform is the market’s first to offer comprehensive behavioral biometrics for MFA in this lightweight, self-service form factor. Unlike other SaaS-based solutions that may specialize in just web interfaces or typing, this new platform brings the company’s deep insights across device types and human interaction to identify unique humans during the authentication process.
“As more organizations move through digital transformation projects, adopting solutions that can offer accuracy, protect privacy, reduce friction – and be agile – is critical,” said Ed Amoroso, Founder and CEO of analyst firm TAG CYBER and former Chief Security Officer at AT&T. “This is especially important for organizations with continuous delivery models for their online services or those concerned with insider threat in our current remote/hybrid work environments.”
The new SaaS packaging is more than a port – it is purpose-built to streamline the BehavioSec API and feature set to offer transparent and passwordless MFA, reduction of step-ups, and replacement of legacy technologies like knowledge-based challenges. In particular, while the new service may seamlessly work in conjunction with one-time passwords (OTP), it can also serve as the means to retire OTP – as OTPs and SMS codes are notorious for their added costs to both business and consumer, friction-full experiences, and recently – vulnerability to a rising trend of SMS fraud.
To ensure rapid time-to-value, the new SaaS solution offers an especially lightweight SDK for easy deployment and integration with Identity & Access Management (IAM) platforms already implemented within customer environments for business, consumer, or workforce protection.
“The vision at the outset of this project was to bring this powerful technology used by the largest financial institutions to a broader audience needing a solution for digital identity protection that supports both compliance and privacy protection,” said BehavioSec VP of Products, Jordan Blake. “And it is not enough to make it available. It has to be highly deployable and user friendly, too - offering high value.”
In addition to the new SaaS version, the commercial release of the vendor-hosted BehavioSense service offers sophisticated fraud organizations the full breadth and depth of BehavioSec fraud prevention technology in a Type 2 SOC 2 and ISO 27001 compliant environment. While the company’s software-based BehavioSense platform has always been fully cloud-compatible for deployment within customer environments (including public cloud), this release comes after the company’s April announcement of Type 1 SOC 2 certification and the subsequent completion of the full Type 2 and ISO requirements.
Today’s announcement follows the company’s 2020 performance that saw a successful 300% growth and a series of developments during the first half of 2021, including significant platform updates and recently, key patent grants. As the company continues to invest in technology innovation and expansion of its go-to-market capabilities, the tripling of its platform footprint into a portfolio play provides a foundation to offer customers greater flexibility with multiple packaging and licensing options tightly aligned to customer requirements and phased implementations.
The new BehavioSense SaaS platform is available now in controlled release with general availability slated for later this year. A free version of the product offering immediate access for developers may be requested online on the BehavioSec website. Customers interested in free, full production trials of any of the company’s solutions may contact the BehavioSec sales team at sales@behaviosec.com. For more information on these new solutions, visit www.behaviosec.com/platform.
1 Gartner, “Market Guide for Online Fraud Detection” Akif Khan, Jonathan Care, 12 July 2021
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About BehavioSec
BehavioSec is the industry pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today. Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat, and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision, and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss.
Founded in the Nordics in 2008 out of groundbreaking research, industry-recognized BehavioSec partners with market leaders and organizations like DARPA, and has earned investment from top investment firms like Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance, and digitally transform your distributed workforce and customer experience. www.behaviosec.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005098/en/
Contact information
W2 Communications for BehavioSec
Carrie Vanbuskirk
pr@behaviosec.com
703 218 3555
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom